Home > Keywords > Thématique > Partenariat

Partenariat

Articles

  • Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER
    28 January 2019, by Jonathan NOWAK

    The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, is announcing today the signing of a scientific collaboration agreement with SERVIER. The companies did not disclose the financial terms of this agreement. This collaboration is part (…)

  • Vect-Horus announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases
    28 January 2019, by Jonathan NOWAK

    The goal of this collaboration is to use VECT-HORUS’ proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease.

  • Vect-Horus and Cerimed announce collaboration to support the development of its theragnostic agents
    17 November 2020, by Elodie DORMES

    Vect-Horus is co-developing with Radiomedix one agent which will enter clinical trials in 2021 for the diagnosis of glioblastoma.
    With Cerimed, Vect-Horus also pursues the investigations on its other theragnostic candidates targeting the Low-Density Lipoprotein Receptor, which has been shown to be expressed at high levels in some tumours, including pancreatic tumours.

  • Vect-Horus is a partner laureate of the ANR RPIB Call 2013 for proposals
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) RPIB Call 2013 for proposals and will be involved in the VEC2Brain project involving 3 academic laboratories. The project will be coordinated by Dr Michel Khrestchatisky, Director of the UMR7259 laboratory (CNRS and Aix-Marseille University) and involves the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA. This project received (…)

  • Vect-Horus is a partner laureate of the ANR MALZ 2010 call for proposals
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2010 call for proposals and will be involved in the ADHOC project coordinated by the UMR7259 laboratory (Coordinator, Pr. François Féron).
    This project received support (label) from the EUROBIOMED Biocluster.

  • Vect-Horus and RadioMedix announce the signing of a LOI to co-develop a Vect-Horus’ radio-theranostic agent for Glioblastoma
    6 March 2019, by Jonathan NOWAK

    Marseille, France- Houston - March 5, 2019 - Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of Glioblastoma Multiforme (GBM) of the brain.
    This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and (…)

  • Relocation of the company to support its development
    1 October 2019, by Elodie DORMES

    Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.

  • Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)
    28 January 2019, by Jonathan NOWAK

    Since its incorporation in 2005 VECT-HORUS is a leading partner of the French academic institutions CNRS and Aix-Marseille University. Indeed, the company as a spin-off of the NICN (UMR7259 CNRS-AMU) now Institute for NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, develops inventions and technologies derived from the “BBB and Neuroinflammation Team”. VECT-HORUS has established a long-term highly efficient collaboration with this (…)

  • Vect-Horus enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.
    26 March 2019, by Jonathan NOWAK

    Vect-Horus S.A.S. announced today the signing of a collaboration and license agreement with Ono Pharmaceutical Co., Ltd., focused on the development of novel molecules targeting neurodegenerative diseases